IRIS Accounts Production v26.3.0.614 OC451632 designated member 1.4.25 31.3.26 31.3.26 0 0 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhOC4516322025-03-31OC4516322026-03-31OC4516322025-04-012026-03-31OC4516322024-03-28OC4516322024-03-292025-03-31OC4516322025-03-31OC451632ns15:EnglandWales2025-04-012026-03-31OC451632ns14:PoundSterling2025-04-012026-03-31OC451632ns10:PartnerLLP12025-04-012026-03-31OC451632ns10:LimitedLiabilityPartnershipLLP2025-04-012026-03-31OC451632ns10:SmallEntities2025-04-012026-03-31OC451632ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-31OC451632ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-31OC451632ns10:LimitedLiabilityPartnershipsSORP2025-04-012026-03-31OC451632ns10:FullAccounts2025-04-012026-03-31OC45163212025-04-012026-03-31OC451632ns10:PartnerLLP22025-04-012026-03-31OC451632ns10:PartnerLLP32025-04-012026-03-31OC451632ns10:RegisteredOffice2025-04-012026-03-31OC451632ns5:CurrentFinancialInstruments2026-03-31OC451632ns5:CurrentFinancialInstruments2025-03-31OC451632ns5:CapitalRedemptionReserve2026-03-31OC451632ns5:CapitalRedemptionReserve2025-03-31OC451632ns5:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-31OC451632ns5:PlantMachinery2025-04-012026-03-31OC451632ns5:IntangibleAssetsOtherThanGoodwill2025-03-31OC451632ns5:IntangibleAssetsOtherThanGoodwill2026-03-31OC451632ns5:IntangibleAssetsOtherThanGoodwill2025-03-31OC451632ns5:PlantMachinery2025-03-31OC451632ns5:PlantMachinery2026-03-31OC451632ns5:PlantMachinery2025-03-31
REGISTERED NUMBER: OC451632 (England and Wales)



















Unaudited Financial Statements

for the Year Ended 31 March 2026

for

A Davies Laboratories International LLP

A Davies Laboratories International LLP (Registered number: OC451632)

Contents of the Financial Statements
for the Year Ended 31 March 2026










Page

General Information 1

Balance Sheet 2

Notes to the Financial Statements 4


A Davies Laboratories International LLP

General Information
for the Year Ended 31 March 2026







DESIGNATED MEMBERS: A W Davies
A Davies Laboratories Ltd
Ms B T Hutton





REGISTERED OFFICE: Unit 7, Marine Works
Embankment Road
Bembridge
Isle of Wight
PO35 5NR





REGISTERED NUMBER: OC451632 (England and Wales)





ACCOUNTANTS: APT
44 The Pantiles
Tunbridge Wells
Kent
TN2 5TN

A Davies Laboratories International LLP (Registered number: OC451632)

Balance Sheet
31 March 2026

31.3.26 31.3.25
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 585,600 658,800
Tangible assets 5 45,101 60,134
630,701 718,934

CURRENT ASSETS
Cash at bank 5,060 2,015

CREDITORS
Amounts falling due within one year 6 1,250 1,250
NET CURRENT ASSETS 3,810 765
TOTAL ASSETS LESS CURRENT LIABILITIES
and
NET ASSETS ATTRIBUTABLE TO
MEMBERS

634,511

719,699

A Davies Laboratories International LLP (Registered number: OC451632)

Balance Sheet - continued
31 March 2026

31.3.26 31.3.25
Notes £    £    £    £   
LOANS AND OTHER DEBTS DUE TO
MEMBERS

596,959

682,682

MEMBERS' OTHER INTERESTS
Capital accounts 229,645 132,658
Other reserves (192,093 ) (95,641 )
634,511 719,699

TOTAL MEMBERS' INTERESTS
Loans and other debts due to members 596,959 682,682
Members' other interests 37,552 37,017
634,511 719,699

The LLP is entitled to exemption from audit under Section 477 of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 for the year ended 31 March 2026.

The members acknowledge their responsibilities for:
(a)ensuring that the LLP keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the LLP as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 relating to financial statements, so far as applicable to the LLP.

The financial statements have been prepared and delivered in accordance with the provisions applicable to LLPs subject to the small LLPs regime.

In accordance with Section 444 of the Companies Act 2006 as applied to LLPs by the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008, the Income Statement has not been delivered.

The financial statements were approved by the members of the LLP and authorised for issue on 29 October 2026 and were signed by:





A W Davies - Designated member

A Davies Laboratories International LLP (Registered number: OC451632)

Notes to the Financial Statements
for the Year Ended 31 March 2026


1. STATUTORY INFORMATION

A Davies Laboratories International LLP is registered in England and Wales. The LLP's registered number and registered office address can be found on the General Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the requirements of the Statement of Recommended Practice, Accounting by Limited Liability Partnerships. The financial statements have been prepared under the historical cost convention.

The functional and presentational currency of the LLP is pounds sterling. Monetary amounts in these financial statements are rounded to the nearest £1, except where otherwise indicated.

Going concern
After reviewing the LLP's forecasts and projections, the members have a reasonable expectation that the LLP has adequate resources to continue in operational existence for the foreseeable future. The LLP therefore continues to adopt the going concern basis in preparing its financial statements.

Significant judgements and estimates
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Intangible assets
Intellectual property is being amortised over its useful economic life of 10 years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance

A Davies Laboratories International LLP (Registered number: OC451632)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026


2. ACCOUNTING POLICIES - continued

Investments
Investments are shown at fair value or where fair value cannot be readily ascertained at cost less impairment. Any aggregate or surplus arising from changes in fair value is recognised through profit and loss.

Financial instruments
Basic financial assets, including trade and other receivables and cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Such assets are subsequently carried at amortised cost, using the effective interest rate method.

Basic financial liabilities including trade and other payables are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Provision for liabilities
Provisions are recognised when the LLP has a present obligation (legal or constructive) as a result of a past event, it is probable that the LLP will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value using a pre-tax discount rate. The unwinding of the discount is recognised as a finance cost in profit or loss in the period it arises.

Investments
Investments are shown at fair value or where fair value cannot be readily ascertained at cost less impairment. Any aggregate or surplus arising from changes in fair value is recognised through profit and loss.

3. EMPLOYEE INFORMATION

The average number of employees during the year was NIL (2025 - NIL).

A Davies Laboratories International LLP (Registered number: OC451632)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026


4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 April 2025
and 31 March 2026 732,000
AMORTISATION
At 1 April 2025 73,200
Charge for year 73,200
At 31 March 2026 146,400
NET BOOK VALUE
At 31 March 2026 585,600
At 31 March 2025 658,800

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 April 2025
and 31 March 2026 80,179
DEPRECIATION
At 1 April 2025 20,045
Charge for year 15,033
At 31 March 2026 35,078
NET BOOK VALUE
At 31 March 2026 45,101
At 31 March 2025 60,134

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.26 31.3.25
£    £   
Other creditors 1,250 1,250

A Davies Laboratories International LLP (Registered number: OC451632)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026


7. RELATED PARTY DISCLOSURES

During the period under review, a licence fee of £30,000 (2025 £30,000) was charged to a company connected with key management personnel.